The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

Plaque Psoriasis Clinical Trial

— ARQ-151-201  

Official title:

A Phase 2b 12-Week Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream 0.3% and ARQ-151 Cream 0.15% Administered Once Daily in Subjects With Chronic Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03638258
• Other study ID #: ARQ-151-201
• Status: Completed
• Phase: Phase 2
• Start date: September 21, 2018
• Est. completion date: May 29, 2019

Study information

• Verified date: August 2022
• Source: Arcutis Biotherapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque psoriasis involving between 2 and 20% body surface area.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 331
• Est. completion date: May 29, 2019
• Est. primary completion date: May 29, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants legally competent to sign and give informed consent

• Males and females ages 18 years and older (inclusive)

• Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator

• Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.

• In good health as judged by the Investigator, based on medical history, physical examination, serum chemistry labs, hematology values, and urinalysis.

• Subjects are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.

Exclusion Criteria:

• Planned excessive exposure of treated area(s) to either natural or artificial sunlight or tanning bed.

• Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.

• Previous treatment with roflumilast cream or its active ingredient

• Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.

• Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.

• Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• Roflumilast Cream 0.3%
Applied once daily for 12 weeks
• Roflumilast Cream 0.15%
Applied once daily for 12 weeks
• Vehicle Cream
Applied once daily for 12 weeks

Locations

Country	Name	City	State
Canada	Arcutis Clinical Site 10	Ajax	Ontario
Canada	Arcutis Clinical Site 25	London	Ontario
Canada	Arcutis Clinical Site 26	Markham	Ontario
Canada	Arcutis Clinical Site 32	Oakville	Ontario
Canada	Arcutis Clinical Site 17	Peterborough	Ontario
Canada	Arcutis Clinical Site 11	Surrey	British Columbia
Canada	Arcutis Clinical Site 18	Surrey	British Columbia
Canada	Arcutis Clinical Site 30	Waterloo	Ontario
Canada	Arcutis Clinical Site 36	Windsor	Ontario
Canada	Arcutis Clinical Site 38	Winnipeg	Manitoba
United States	Arcutis Clinical Site 35	Beverly Hills	California
United States	Arcutis Clinical Site 39	Bexley	Ohio
United States	Arcutis Clinical Site 34	Clinton Township	Michigan
United States	Arcutis Clinical Site 19	College Station	Texas
United States	Arcutis Clinical Site 33	Detroit	Michigan
United States	Arcutis Clinical Site 20	Fridley	Minnesota
United States	Arcutis Clinical Site 14	High Point	North Carolina
United States	Arcutis Clinical Site 13	Houston	Texas
United States	Arcutis Clinical Site 37	Houston	Texas
United States	Arcutis Clinical Site 21	Louisville	Kentucky
United States	Arcutis Clinical Site 12	Miami	Florida
United States	Arcutis Clinical Site 22	New York	New York
United States	Arcutis Clinical Site 31	Norfolk	Virginia
United States	Arcutis Clinical Site 29	Northridge	California
United States	Arcutis Clinical Site 15	Pittsburgh	Pennsylvania
United States	Arcutis Clinical Site 23	San Antonio	Texas
United States	Arcutis Clinical Site 28	San Diego	California
United States	Arcutis Clinical Site 16	Sanford	Florida
United States	Arcutis Clinical Site 27	Santa Monica	California
United States	Arcutis Clinical Site 24	Webster	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Arcutis Biotherapeutics, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6	The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') at Week 6 is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.	Week 6
Secondary	Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear'	The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.	Weeks 4, 8, and 12
Secondary	Change From Baseline in Modified Psoriasis Area Severity Index (mPASI) Score	The percent change from baseline in mPASI score is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. For scoring, the body is divided into four sections (head [h]: 10% of a person's skin; arms [a] 20%; trunk [t] 30%; legs (l] 40%); for each section, the percent of area involved is estimated from 0 (0% involved) to 6 (90 to 100% involved). Then, within each area, the severity is estimated by three clinical signs: erythema ('E'; redness), induration ('T'; thickness), and desquamation ('S'; scaling). Severity parameters are measured on a scale of 0 to 4, from none to maximum severity possible. Each of these areas is scored by itself, and then the four scores are combined into the final mPASI, using the formula mPASI = 0.1 (Eh + Th + Sh) Ah + 0.2 (Ea + Ta + Sa) Aa + 0.3 (Et + Tt + St) At + 0.4 (El + Tl + Sl) Al.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percent Change From Baseline in Body Surface Area (BSA) Affected	The BSA affected by psoriasis was determined by the subject's hand method, where the subject's hand (including fingers) surface area was assumed to equal 1% of BSA. The mean percent change from baseline in BSA is presented.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Plus a 2-Grade Improvement From Baseline	The percentage of participants with an IGA score of 0 ('clear') or 1 ('almost clear') plus a 2-grade improvement from baseline is reported. The IGA is 5-point scale assessing the severity of plaque psoriasis, with scores ranging from 0 ('clear') to 4 ('severe'), with higher scores indicating greater plaque severity.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percentage of Participants With an Intertriginous Area Investigator Global Assessment (I-IGA) Score of 'Clear' or 'Almost Clear' Who Had at Least Mild Lesions at Baseline	The percentage of participants (who had intertriginous area involvement with an I-IGA score of at least mild at baseline) with at least a 2-grade improvement in I-IGA score at Weeks 4, 6, 8, and 12 is presented.	Weeks 4, 6, 8, and 12
Secondary	Change From Baseline in Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score	The WI-NRS is a simple, single-item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours. The mean (SD) change in WI-NRS score from baseline is presented.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percentage of Participants With Baseline Worst Itch-Numeric Rating Scale (WI-NRS) Pruritus Score =6 Who Experienced a 4-point Reduction	The percentage of participants who had baseline WI-NRS scores =6 who achieved a 4-point reduction in WI-NRS score at Weeks 4, 6, 8, and 12 is reported. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the subject experienced in the previous 24 hours.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-75 (mPASI-75) Compared to Baseline	The percentage of subjects achieving a 75% reduction in mPASI (eg, mPASI-75) score relative to baseline is presented. The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Percentage of Participants Achieving a Modified Psoriasis Area Severity Index-90 (mPASI-90) Compared to Baseline	The mPASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 ('no disease') to 72 ('maximal disease'), with higher scores indicating greater severity. The percentage of subjects achieving a 90% reduction in mPASI (eg, mPASI-90) score relative to baseline is presented.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Change From Baseline in Psoriasis Symptom Diary (PSD) Total Score	The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 11 ("worst imaginable symptoms"). Scores range from 0 to 176, with higher scores indicating greater symptom severity. The mean (SD) change in PSD total score relative to baseline is presented for each treatment arm.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Change From Baseline in Itch-Related Sleep Loss Numeric Rating Scale (NRS) Score	The Itch-Related Sleep Loss NRS is a single item scale scored from 0 ("no itch-related sleep loss") to 10 ("itch-related sleep loss as bad as it could be") assessing the severity of itch-related sleep loss in the past 24 hours. The mean (SD) change from the baseline NRS score is presented for each treatment arm.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Change From Baseline in Dermatology Life Quality Index (DLQI) Score	The DLQI is a 10-item scale asking subject to rate the severity of symptoms during the past week. Each item is scored from 0 ("not at all" or "not relevant") to 3 or 4 ("very much") [2 questions are scored 0 to 3 and 8 questions are scored 0 to 4]. The total DLQI score ranges from 0 to 48, with higher scores indicating greater symptom severity. The mean (SD) change from baseline DLQI score is presented.	Baseline (Day 1) and Weeks 4, 6, 8, and 12
Secondary	Responses to Individual Questions of the Psoriasis Symptom Diary (PSD)	Two items from the PSD asking participants to rate the overall severity of psoriasis-related itching and pain during the past 24 hours are presented. Each item is scored on an 11-point scale ranging from 0 ("no symptom") to 10 ("worst imaginable symptom"), with lower scores indicating lower symptoms severity. The mean (SD) score is presented for each treatment arm.	Weeks 4, 6, 8, and 12